Aevi Genomic Medicine, LLC, a Cerecor company
Closed portfolio with an early-phase archive tilt
According to ClinicalTrials.gov-derived indexes, Aevi Genomic Medicine, LLC, a Cerecor company sits in the top decile of US sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count).
Aevi Genomic Medicine, LLC, a Cerecor company: 10 sponsored US clinical trials, none currently recruiting.
Aevi Genomic Medicine, LLC, a Cerecor company sponsors 10 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 9 completed. 0 of these trials are in Phase 3-4 (later-stage) and 8 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Attention Deficit Disorder With Hyperactivity, with 2 trials.
Top-decile sponsor footprint
Aevi Genomic Medicine, LLC, a Cerecor company ranks in the top decile of sponsors by registered trial count (#1,331 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
9 of 10 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (90.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
10 total, page 1 of 1
Clinical Trial to Evaluate CERC-002 in Adults With COVID-19 Pneumonia and Acute Lung Injury
NCT04412057
PART B: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and Without mGluR Mutations
NCT03609619
PART A: Efficacy and Safety of AEVI-001 in Children and Adolescents With ADHD and With mGluR Mutations
NCT03265119
A Non-interventional Study to Identify Children and Adolescents With ADHD and With or Without mGLuR Mutations
NCT03233867
Pharmacokinetic and Tolerability Study of NFC-1 in Subjects Aged 6-17 Years With ADHD
NCT03006367
Safety and Efficacy Study of NFC-1 in Subjects Aged 12-17 Years With 22q11.2DS & Associated Neuropsychiatric Conditions
NCT02895906
Efficacy and Safety of NFC-1 in Adolescents With Genetic Disorders Impacting mGluR and ADHD
NCT02777931
A Noninterventional Genotype/Phenotype Study of mGluR Mutations in Children and Adolescents With ADHD
NCT02811211
TARGTEPO Treatment for Anemia in PD US Trial
NCT02468414
Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder
NCT02286817
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 3 |
| Phase 2 | 5 |
How the Aevi Genomic Medicine, LLC, a Cerecor company early-phase archive is shaped
10 indexed studies, none listed as recruiting (0% open); 9 completed (90%).
Phase mix: 0 late (III/IV) vs 8 early (I/II) (early-phase heavy).
Top condition: Attention Deficit Disorder With Hyperactivity (2 trials), 2 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Aevi Genomic Medicine, LLC, a Cerecor company: archived-pipeline peers nationwide
Peers matched on 10 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Aevi Genomic Medicine, LLC, a Cerecor company sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 10 archived trials
- Adamas Pharmaceuticals · 10 trials · 0% recruiting
- Adverum Biotechnologies · 10 trials · 30% recruiting
- Agouron Pharmaceuticals · 10 trials · 0% recruiting
- Aimmune Therapeutics · 10 trials · 10% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Aevi Genomic Medicine, LLC, a Cerecor company page
10 registered trials is a research-attention snapshot, not an endorsement of Aevi Genomic Medicine, LLC, a Cerecor company or any single study.
- None of Aevi Genomic Medicine, LLC, a Cerecor company's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Attention Deficit Disorder With Hyperactivity is the condition Aevi Genomic Medicine, LLC, a Cerecor company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Attention Deficit Disorder With Hyperactivity trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Aevi Genomic Medicine, LLC, a Cerecor company pipeline card: 10 registered trials from official public datasets.Report a data error.